Abcam, ab269574, Anti-Cytokeratin 13 antibody [AE8] - BSA and Azide free

Size: 100µg
Mouse Monoclonal Cytokeratin 13 antibody. Carrier free. Suitable for WB, IHC-P, ICC/IF, IHC-Fr and reacts with Human samples.
Key facts
Host species:Mouse,
Clonality:Monoclonal,
Clone number:AE8,
Isotype:IgG,
Light chain type:kappa,
Carrier free:Yes,
Reacts with:Human,
Applications:ICC/IF, IHC-Fr, WB, IHC-PSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
This antibody is specific for Cytokeratin 13, which is a marker for oesophageal type differentiation which is expressed by various internal stratified epithelia.
ab269574 is the carrier-free version of
ab16112
Want a custom formulation?
This antibody clone is manufactured by Abcam. If you require a custom buffer formulation or conjugation for your experiments, please contact orders@abcam.com
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein G, Storage buffer-Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-Do Not Freeze

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Cytokeratin 13 also known as KRT13 or CK13 is a type I intermediate filament protein weighing approximately 44 kDa. It is one of the cytokeratin types that plays a critical role in the mechanical stability and integrity of epithelial cells. Cytokeratin 13 is expressed in the stratified squamous epithelium particularly in the upper layers of non-cornified epithelia which include the esophagus tongue and cervix. This protein forms heteropolymers with type II keratins contributing to the cytoskeletal filament network within epithelial cells.
Biological function summary
This protein participates in maintaining the structural framework and dynamics within epithelial tissues. As part of the cytoskeletal complex cytokeratin 13 supports cellular resilience against mechanical stress. It interacts with other cytokeratins contributing to the formation of a robust keratin filament network essential for epithelial cell function and differentiation. Its expression and regulation are key to the homeostasis of the tissues where it is found ensuring proper cell division and tissue integrity.
Pathways
Cytokeratin 13 integrates into epithelial cell differentiation and repair processes. It is involved in the epithelial-mesenchymal transition (EMT) pathway important for tissue development wound healing and cancer metastasis. During the EMT process cytokeratin 13 often works alongside proteins like E-cadherin and Vimentin mediating changes in epithelial cell architecture and polarity. This modulation is essential for cellular plasticity and response to environmental cues.
Cytokeratin 13 has associations with certain epithelial tissue abnormalities such as oral squamous cell carcinoma and a subgroup of inherited blistering diseases like epidermolysis bullosa. In oral squamous cell carcinoma dysregulation of cytokeratin 13 expression may indicate tumor progression and metastasis. In epidermolysis bullosa mutations affecting keratin interactions including those with other keratins like cytokeratin 14 can lead to fragile skin and mucosal surfaces resulting in increased susceptibility to physical damage and impaired healing.